Do analysts prefer BPTH or SNOA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate BPTH or NCNA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, BPTH or NCNA?

NuCana is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Path N/A N/A -$16.08M -$1.09 N/A NuCana N/A N/A -$38.71M -$3.81 N/A

Is BPTH or NCNA more profitable?

NuCana's return on equity of -41.90% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Bio-Path N/A -2,842.40% -337.48% NuCana N/A -41.90% -33.69%

Do analysts prefer BPTH or ENVB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, BPTH or ENVB?

Enveric Biosciences is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Path N/A N/A -$16.08M -$1.09 N/A Enveric Biosciences N/A N/A -$8.77M -$12.65 N/A

Is BPTH or ENVB more profitable?

Enveric Biosciences' return on equity of -168.04% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Bio-Path N/A -2,842.40% -337.48% Enveric Biosciences N/A -168.04% -145.95%

Do analysts prefer GELS or BPTH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, GELS or BPTH?

Gelteq has higher revenue and earnings than Bio-Path. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gelteq $110K 86.97 -$4.30M N/A N/A Bio-Path N/A N/A -$16.08M -$1.09 N/A

Is GELS or BPTH more profitable?

Gelteq's return on equity of 0.00% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Gelteq N/A N/A N/A Bio-Path N/A -2,842.40% -337.48%

Do analysts prefer BPTH or PCSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Heatwurx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, BPTH or PCSA?

Heatwurx is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Path N/A N/A -$16.08M -$1.09 N/A Heatwurx N/A N/A -$13.56M -$4.23 N/A

Is BPTH or PCSA more profitable?

Heatwurx's return on equity of -394.25% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Bio-Path N/A -2,842.40% -337.48% Heatwurx N/A -394.25% -244.46%

Bio-Path (BPTH) Competitors

$0.02 -0.01 (-25.00%)

As of 09/3/2026 03:57 PM Eastern

Compare

BPTH vs. SNOA, NCNA, ENVB, GELS, and PCSA

Should you buy Bio-Path stock or one of its competitors? Bio-Path's main competitors and comparable companies include Sonoma Pharmaceuticals (SNOA), NuCana (NCNA), Enveric Biosciences (ENVB), Gelteq (GELS), and Heatwurx (PCSA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Bio-Path compare to Sonoma Pharmaceuticals?

Bio-Path (NASDAQ:BPTH) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Bio-Path has a beta of -0.53, suggesting that its stock price is 153% less volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bio-Path has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -10.33%. Sonoma Pharmaceuticals' return on equity of -21.41% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Path	N/A	-2,842.40%	-337.48%
Sonoma Pharmaceuticals	-10.33%	-21.41%	-6.08%

5.7% of Bio-Path shares are held by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 0.7% of Bio-Path shares are held by insiders. Comparatively, 1.0% of Sonoma Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Sonoma Pharmaceuticals has higher revenue and earnings than Bio-Path. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A
Sonoma Pharmaceuticals	$21.92M	0.29	-$3.17M	-$1.22	N/A

In the previous week, Bio-Path's average media sentiment score of 0.00 equaled Sonoma Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Bio-Path	Neutral
Sonoma Pharmaceuticals	Neutral

Summary

Sonoma Pharmaceuticals beats Bio-Path on 7 of the 11 factors compared between the two stocks.

How does Bio-Path compare to NuCana?

Bio-Path (NASDAQ:BPTH) and NuCana (NASDAQ:NCNA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

NuCana's return on equity of -41.90% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Path	N/A	-2,842.40%	-337.48%
NuCana	N/A	-41.90%	-33.69%

Bio-Path has a beta of -0.53, meaning that its share price is 153% less volatile than the broader market. Comparatively, NuCana has a beta of 2.23, meaning that its share price is 123% more volatile than the broader market.

5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 44.0% of NuCana shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by insiders. Comparatively, 31.2% of NuCana shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NuCana is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A
NuCana	N/A	N/A	-$38.71M	-$3.81	N/A

In the previous week, Bio-Path's average media sentiment score of 0.00 equaled NuCana'saverage media sentiment score.

Company	Overall Sentiment
Bio-Path	Neutral
NuCana	Neutral

Summary

NuCana beats Bio-Path on 6 of the 9 factors compared between the two stocks.

How does Bio-Path compare to Enveric Biosciences?

Bio-Path (NASDAQ:BPTH) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

In the previous week, Bio-Path's average media sentiment score of 0.00 equaled Enveric Biosciences'average media sentiment score.

Company	Overall Sentiment
Bio-Path	Neutral
Enveric Biosciences	Neutral

Enveric Biosciences is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A
Enveric Biosciences	N/A	N/A	-$8.77M	-$12.65	N/A

Bio-Path has a beta of -0.53, meaning that its share price is 153% less volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

5.7% of Bio-Path shares are held by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are held by institutional investors. 0.7% of Bio-Path shares are held by insiders. Comparatively, 2.4% of Enveric Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Enveric Biosciences' return on equity of -168.04% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Path	N/A	-2,842.40%	-337.48%
Enveric Biosciences	N/A	-168.04%	-145.95%

Summary

Enveric Biosciences beats Bio-Path on 7 of the 9 factors compared between the two stocks.

How does Bio-Path compare to Gelteq?

Gelteq (NASDAQ:GELS) and Bio-Path (NASDAQ:BPTH) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

5.7% of Bio-Path shares are held by institutional investors. 0.7% of Bio-Path shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Gelteq's return on equity of 0.00% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gelteq	N/A	N/A	N/A
Bio-Path	N/A	-2,842.40%	-337.48%

Gelteq has a beta of -0.41, meaning that its stock price is 141% less volatile than the broader market. Comparatively, Bio-Path has a beta of -0.53, meaning that its stock price is 153% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Gelteq had 1 more articles in the media than Bio-Path. MarketBeat recorded 1 mentions for Gelteq and 0 mentions for Bio-Path. Gelteq's average media sentiment score of 0.00 equaled Bio-Path'saverage media sentiment score.

Company	Overall Sentiment
Gelteq	Neutral
Bio-Path	Neutral

Gelteq has higher revenue and earnings than Bio-Path.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gelteq	$110K	86.97	-$4.30M	N/A	N/A
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A

Summary

Gelteq beats Bio-Path on 7 of the 9 factors compared between the two stocks.

How does Bio-Path compare to Heatwurx?

Bio-Path (NASDAQ:BPTH) and Heatwurx (NASDAQ:PCSA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Heatwurx's return on equity of -394.25% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Path	N/A	-2,842.40%	-337.48%
Heatwurx	N/A	-394.25%	-244.46%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Heatwurx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 91.9% of Heatwurx shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by insiders. Comparatively, 3.5% of Heatwurx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Heatwurx is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A
Heatwurx	N/A	N/A	-$13.56M	-$4.23	N/A

In the previous week, Heatwurx had 1 more articles in the media than Bio-Path. MarketBeat recorded 1 mentions for Heatwurx and 0 mentions for Bio-Path. Bio-Path's average media sentiment score of 0.00 equaled Heatwurx'saverage media sentiment score.

Company	Overall Sentiment
Bio-Path	Neutral
Heatwurx	Neutral

Bio-Path has a beta of -0.53, indicating that its share price is 153% less volatile than the broader market. Comparatively, Heatwurx has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

Summary

Heatwurx beats Bio-Path on 8 of the 10 factors compared between the two stocks.

Get Bio-Path News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BPTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BPTH vs. The Competition

Export

Metric	Bio-Path	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$809K	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-0.01	787.28	273.30	25.25
Price / Sales	N/A	755.95	618.15	97.66
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	0.02	12.32	12.89	6.14
Net Income	-$16.08M	$2.82B	$3.47B	$349.01M
7 Day Performance	N/A	2.58%	0.53%	-0.31%
1 Month Performance	N/A	6.94%	5.64%	0.64%
1 Year Performance	N/A	9.44%	25.31%	14.83%

Bio-Path Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BPTH Bio-Path	N/A	$0.02 -25.0%	N/A	-87.8%	$809K	N/A	N/A	10	Gap Down High Trading Volume
SNOA Sonoma Pharmaceuticals	0.3852 of 5 stars	$1.37 +1.5%	N/A	-71.4%	$6.56M	$21.92M	N/A	180
NCNA NuCana	0.8599 of 5 stars	$1.49 +1.4%	N/A	-53.0%	$6.20M	N/A	N/A	30	Positive News
ENVB Enveric Biosciences	0.6778 of 5 stars	$1.38 -5.5%	N/A	-88.6%	$6.18M	N/A	N/A	20
GELS Gelteq	0.817 of 5 stars	$0.57 +3.4%	N/A	-20.3%	$6.06M	$110K	N/A	N/A	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BPTH) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bio-Path (BPTH) Competitors

BPTH vs. SNOA, NCNA, ENVB, GELS, and PCSA

How does Bio-Path compare to Sonoma Pharmaceuticals?

Summary

How does Bio-Path compare to NuCana?

Summary

How does Bio-Path compare to Enveric Biosciences?

Summary

How does Bio-Path compare to Gelteq?

Summary

How does Bio-Path compare to Heatwurx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTH vs. The Competition

Bio-Path Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bio-Path (BPTH) Competitors

BPTH vs. SNOA, NCNA, ENVB, GELS, and PCSA

How does Bio-Path compare to Sonoma Pharmaceuticals?

Which has more risk and volatility, BPTH or SNOA?

Do analysts prefer BPTH or SNOA?

Is BPTH or SNOA more profitable?

Do institutionals & insiders believe in BPTH or SNOA?

Which has better earnings & valuation, BPTH or SNOA?

Does the media favor BPTH or SNOA?

Summary

How does Bio-Path compare to NuCana?

Is BPTH or NCNA more profitable?

Which has more risk and volatility, BPTH or NCNA?

Do institutionals and insiders believe in BPTH or NCNA?

Do analysts rate BPTH or NCNA?

Which has better valuation and earnings, BPTH or NCNA?

Does the media favor BPTH or NCNA?

Summary

How does Bio-Path compare to Enveric Biosciences?

Does the media refer more to BPTH or ENVB?

Which has preferable earnings and valuation, BPTH or ENVB?

Which has more volatility & risk, BPTH or ENVB?

Do insiders and institutionals believe in BPTH or ENVB?

Do analysts prefer BPTH or ENVB?

Is BPTH or ENVB more profitable?

Summary

How does Bio-Path compare to Gelteq?

Do insiders & institutionals believe in GELS or BPTH?

Is GELS or BPTH more profitable?

Which has more volatility and risk, GELS or BPTH?

Do analysts prefer GELS or BPTH?

Does the media refer more to GELS or BPTH?

Which has better valuation and earnings, GELS or BPTH?

Summary

How does Bio-Path compare to Heatwurx?

Is BPTH or PCSA more profitable?

Do analysts prefer BPTH or PCSA?

Do insiders and institutionals hold more shares of BPTH or PCSA?

Which has stronger earnings & valuation, BPTH or PCSA?

Does the media favor BPTH or PCSA?

Which has more risk & volatility, BPTH or PCSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTH vs. The Competition

Bio-Path Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools